Larimar Therapeutics

$8.26 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Larimar Therapeutics

Larimar Therapeutics Inc., formerly Zafgen, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for complex rare diseases using its cell penetrating peptide technology platform. The Company’s protein replacement therapy platform provides disease-modifying therapies that intends to deliver missing proteins inside the machinery of cells to treat devastating rare diseases that have no treatments available. The Company’s lead product candidate, CTI-1601, is a recombinant fusion protein intended to deliver human frataxin (FXN) into the mitochondria of patients with Friedreich’s ataxia (FA). CTI-1601 is in Phase I clinical program. The Company intends to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.

Stock Analysis

last close $8.03
1-mo return -39.9%
3-mo return -54.4%
avg daily vol. 241.77T
52-week high 25.87
52-week low 7
market cap. $128M
forward pe -
annual div. -
roe -78.7%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 92.7%
baraka

Subscribe now for daily local and international financial news

Subscribe